Examining the secret hideouts of ovarian cancer – the review by BIOMEDICA CRO
Every year almost 240,000 new cases of ovarian cancers are diagnosed, leading to the death of over 150,000 women worldwide. Out of all ovarian cancers, high-grade serous ovarian, peritoneal or fallopian-tube cancer (HGSC) is the most common subtype and the cause of 70–80% of all ovarian cancer-related deaths.
Researchers at the University of Helsinki have uncovered how tumor cells interact with the immune system in ovarian cancer. Utilizing a novel imaging technology, the researchers characterized more than 110,000 individual cells from clinical ovarian cancer samples.
“By increasing our understanding of how tumor genes trick the immune system, we will be able to develop more effective ways to activate the body’s own immune defenses to kill the cancer cells,” doctoral researcher Inga-Maria Launonen, BM says.
The results of the study confirm the significance of the interaction between tumor and immune cells in identifying new and more effective therapies as well as in choosing the right therapy for each patient.
Associate professor Anniina Färkkilä, the corresponding author of the study, said: “Our findings will enable us to tailor precision immuno- and combination therapies that have the potential to even cure ovarian cancer in the future”.
Please follow the link for more info.
BIOMEDICA CRO is proud to participate in research on biomarkers, tests, and developing new therapeutic approaches to human disease.
We have good access to donors with different cancer types, including ovarian cancer.
Our team is ready to collect high-quality human biospecimens to provide scientists with all needed samples and associated data for their studies. Please email us to start our collaboration: office@biomedica-cro.com or visit our page with relevant biospecimens options.
